July 31 (Reuters) - Novo Nordisk said on Friday
its experimental drug failed to reduce the risk of major
cardiovascular events in a late-stage trial involving patients
with cardiovascular disease, chronic kidney disease and
inflammation.
(Reporting by Siddhi Mahatole in Bengaluru)